

Q3 FY26 Quarterly Investor Presentation & Webinar

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to provide below its Q3 FY26 Investor Presentation and Investor Webinar with CEO, Dr Luke Reid presenting.

Quarterly Investor Webinar

Presented by: CEO, Dr Luke Reid

Date & Time: 11:00am AEST on Thursday, 30 April 2026

Webinar Registration: Registration is required to attend the Quarterly Investor Webinar. Please register for the Webinar via Microba's Investor Hub at the following link: <https://ir.microba.com/webinars/7eXZ2P-q3-fy26-quarterly-investor-webinar>

Webinar Recording: A recording will be made available at the same link following the conclusion of the live webinar.

Submit Your Questions

We invite investors and interested parties to submit questions ahead of the Quarterly Investor Webinar through the 'Ask a question' section of Microba's interactive investor platform by following this link:

<https://ir.microba.com/webinars/7eXZ2P-q3-fy26-quarterly-investor-webinar>

Stay Informed

To receive notifications when Microba releases its Quarterly Reports & Appendix 4C, Investor Presentations, and other key announcements, sign up to the Microba Investor Hub:

1. Visit <https://ir.microba.com/welcome>
2. Follow the prompts to sign up for an account.
3. Complete your account profile.

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

luke.reid@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621



Q3 FY26 Results

Building the platform for personalised, microbiome-based healthcare

ASX: MAP
30 APRIL 2026

Authorised for release by the Board of Directors



Disclaimer



This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Key Risks & Forward Financial Information Assumptions



Forward Financial Information Assumptions

The achievement of the FY26 forward information & ~3-year strategic objectives detailed in slide 4 is based on the below key assumptions, and deviation in the Company's ability to achieve or not achieve these key assumptions, may materially affect the Company's ability to execute these objectives. Refer to slide 2 for the general disclaimer relating to 'future performance'. The assumptions specific to the FY26 forward information & ~3-year strategic objectives are set out below.

FY26 Outlook Assumptions

- YoY core test volume growth of 100% assumes continued clinician adoption growth in Australia and the UK market.
 - Increased clinician adoption, including continued growth of new clinician accounts and maintenance of existing test referral rates in Australia & the United Kingdom
 - New product feature releases.

FY26 break-even milestones - Assumptions

- Based on operating break-even at a regional level (forecasted to be achieved at test volumes of >24,000, split across Australia and the UK)
- Break-even figures are on a regional EBITDA basis only and exclude Corporate, Product Development Expenditure and Share Based Payments expense.
- Australia break-even and UK break-even figures are based on forecast test pricing, targeted gross margins, and assumed operating cost structures for each geography.
- Test pricing and gross margins are assumed to remain stable over FY25–FY26, with no material changes.
- Operational costs assume continued efficiencies from fixed infrastructure and modest scaling of commercial and support functions, including advancement and implementation of product-assisted/led growth models.
- UK break-even assumptions are modelled using an AUD:GBP exchange rate of 0.48.
- Assumes no material disruption from regulatory changes, macroeconomic & geopolitical shifts, or competitive pricing actions.
- Forecasts are contingent on execution of FY26 revenue plan and sufficient capital allocation to support commercial execution and product development.

~3 Year Strategic Objective Assumptions

Group EBITDA Break-even - Assumptions

- Group break-even assumes successful execution of the FY26 regional break-even milestones (see above), followed by further scale in existing markets.

- Assumes that Operating Expenses, Product Development and Corporate Expenditure grow at a rate below revenue growth, enabling operating leverage.
- Assumes that new geographies or product development programs do not materially increase operating expenditure during the period.

Strong YoY Core Test Growth – Australia & United Kingdom – Assumptions

- Growth targets assumed in the Group EBITDA Break-even plan assumes continued strong clinical adoption by innovator and early adopter clinicians and broader market penetration.
- Assumed strong YoY growth is dependent on the availability of sufficient capital to support planned commercial expansion, product development and operational scaling. In the event that capital is not secured at anticipated levels, these objectives may be delayed or may not be achieved.

Initial Market Penetration – United States & Europe – Assumptions

- Assumed core test pricing aligned with existing competitor predicate tests in market.
- Entry into the US and Europe is expected to be limited to one initial geography in each region.
- Assumes Laboratory Developed Test (LDT) regulatory pathway remains accessible in the US, and CLIA accreditation is achieved for Microba central laboratory in Australia to service the initial development of the US market
- Assumes successful establishment of laboratory service partnership and logistics with The Doctors Laboratory (a subsidiary of Sonic Healthcare) to service volume from the UK and Europe
- Assumes supportive regulatory, geopolitical and tariff environment and no material delays in market access.
- Assumes no requirement for reimbursement, cash pay sales are considered only.
- Modest investment has been included, no material CAPEX expenditure has been incorporated, with existing and partner laboratories utilised to service growth in test volume.

Transformative Patient Outcomes – Assumptions

- Qualitative and based on the frequency of patient outcomes shown from existing study data on Microba's core tests, and the anticipated growth in patient test usage and resulting continued growth in clinician adoption

“We are building the platform for personalised, microbiome-based healthcare.”

FY26

FY25

Grow early clinical adoption.
UK market expansion.

161%

YoY core test growth

\$15.67m

Revenue

12,631

Core test volume

Expand clinical adoption.
Break-even in Australia &
United Kingdom¹.

>100%

YoY core test growth

Regional Break-even

In Australia & United Kingdom¹

>24,000

Core test volume

~3 Year Strategic Objective

Strong penetration of
innovator & early adopter
clinicians. Transformative
patient outcomes across
core regions.

Break-even

Group EBITDA

Australia

Strong YoY growth

United Kingdom

Strong YoY growth

United States

Momentum in first state

Europe

Momentum in first country

The information on this slide includes forward financial information (Forward Financial Information). The Forward Financial Information has been prepared by Microba Life Sciences Ltd based on management best estimate assumptions which relate to future event(s) that Microba expects to occur and actions that Microba expects to take and are also subject to uncertainties and contingencies, which are often outside the control of Microba. While all reasonable endeavours have been made to ensure both the robustness of the assumptions on which the Forward Financial Information is based and that such assumptions are true, complete and accurate, such assumptions are generally future-oriented and therefore speculative in nature. 'Refer to slide 2 Financial Information Assumptions') for detail on both the assumptions and risks underpinning the FY26 numbers and ~3 Year Strategic Objective.

Section 1


Q3 FY26 Financial Highlights

Core Testing Revenues up 99% YoY.

Q3 core test volumes up 58%

Annualised run rate of 23,000+

**On track for >24,000 FY26 core test volume
and regional break-even guidance**



Section 2


Q3 FY26 Business Highlights

Sub-Section 2.1

Key Highlights


Winning key accounts in Australia

- In Australia, adoption has now moved beyond innovators into early adopters, increasingly characterised by enterprise-style contracts with healthcare clinics.
- These accounts when signed and activated, represent meaningful recurring volume potential.
- There are over 130 key account targets currently in the pipeline in Australia, with an estimated ordering potential of over 60,000 tests per annum.
- Since we commenced targeting these key accounts in November we have already signed 27, representing a total estimated ordering potential of over 19,500 tests per annum.
- As at end of March those 27 key accounts had already sold 2,874 tests, growing strongly month on month – March sales from these accounts annualised is 7,440 tests, showing the significant growth opportunity ahead from these accounts.



UK Testing Market Outperforming Australia

- Leveraging the existing acquired customer base in the UK, we are continuing to see UK adoption outperform AU adoption at the equivalent time post launch.
- We expect this to continue to accelerate across 2026 leveraging the historical Invivo customer base, product advancement and feature releases, and global marketing efficiency.



New Product Feature Releases

New Test Release

Targeting release in Q1 FY27

On track for a major new product release in Q1 FY27. This product is the culmination of several years of leadership at the forefront of this new diagnostic category. This new product represents a meaningful leap in the clinical application of complete microbiome and gut testing, and is expected to open up our serviceable addressable market to more medical doctors, which represent a significant next segment of the healthcare practitioner market for our tests.

This new product is live now with a beta cohort of 25 practitioners across AU and UK: multiple parts of the product are already delivering clinical value and receiving positive feedback, the new product is powered by Microba's proprietary one-of-a-kind Clinical Logic Engine

The graphic features the Microba logo at the top left. The central text reads "COMING SOON" in large, bold, white letters, followed by "The full picture of gut health - in one test." Below this, a tablet displays a patient dashboard for "Linda Smith" with a navigation bar for "Key Findings & Actions", "12 Interpretations", "Health System", and "Specialty Referral". The dashboard is divided into two columns: "See what matters" and "Know what to do".

See what matters:

- Existent**
Mucus disrupting microbiome
Suggests the microbiome is contributing to disruption to the protective layer of mucus lining the gut epithelium. Disruption of the protective mucus layer can expose the gut epithelium to damage, inflammation and pathogen invasion.
- Existent**
Intestinal permeability link
Suggests that the ability of the gut barrier to regulate the passage of molecules may be compromised due to an imbalance in the gut microbiome, which may have negative health impacts.
- Possibly Existent**
Reduced colonic butyrate availability
Suggests reduced use of butyrate by the colon cells. Butyrate is the primary energy source for colon cells, supporting gut barrier integrity. Insufficient production of butyrate and/or high levels of hydrogen sulphide can lead to colonic butyrate deprivation, which may undermine the integrity of the gut barrier.

Know what to do:

- Very high fibre diet**
A very high fibre diet could address a pro-inflammatory and mucus-disrupting microbiome via mucin degradation pathways. Consider aiming for greater than 50g of fibre per day from fruits and vegetables, wholegrains, legumes, nuts and seeds.
- Polyphenol-rich foods**
Increasing polyphenols in the diet could address the microbiome link to intestinal permeability and systemic inflammation via indole-3-propionic acid (IPA) pathways. Consider 3 servings/day of foods such as berries, blood oranges, pomegranate and green tea.
- Partially hydrolysed guar gum (PHGG)**
PHGG supplementation could address reduced colonic butyrate availability via butyrate pathways. Consider a gradual increase in dose to 5g/day.

New Product Feature Releases

v1.5 Sampling Kit

Released for Microbiome Explorer range in February 2026

Better customer experience and lower cost of goods have been delivered via a new Microbiome Explorer sampling Kit (v1.5) across AU and UK, introducing refreshed Microba branding, simplified device labelling, and a new toilet-collection device to drive improved sample collection success, reduced inbound support queries and requests for kit replacement.




New Product Feature Releases

Clinical Integration Platform

Targeted for Q4 FY26

Microba's Clinical Integration Platform embeds our tests into the clinical systems GPs and specialists already use, so they can order, receive results and act on them without leaving their existing practice management software and workflows.


In March we executed a commercial partnership agreement with Best Practice - the dominant GP practice management software in Australia, used by approximately 28,000 GPs and the software of choice for every early adopter GP we've interviewed. This will support ordering of Microba's product catalogue via Practice Management Software used in traditional medical workflows across Australia. Best Practice is the first partner on Microba's Clinical Integration Platform, with additional partner integrations planned for the quarters ahead.



Sub-Section 2.2



Diagnostic Results

Growing Microbiome Explorer sales and clinical adoption in Australia





- Record Q3 Microbiome Explorer AU tests sales of 4,786
- Q3 Microbiome Explorer AU annualised run-rate of ~20,000 tests sold
- Q3 Microbiome Explorer AU Ordering Clinicians: 824
- Supported by key clinic account success, focused clinician field engagement, and improved lifecycle marketing

Strong progress in UK market development for Microbiome Explorer



- Q3 Microbiome Explorer UK test sales of 816
- Q3 Microbiome Explorer UK annualised run-rate of ~3,000 tests sold
- Q3 Microbiome Explorer UK Ordering Clinicians: 266
- Supported by focused clinician field engagement, top-of-funnel qualification, conversion and activation of new accounts.

Steady MetaPanel sales and clinical adoption in Australia





- Steady Q3 MetaPanel test sales of 204 tests
- Focus remains on organic development of Gastroenterology specialists which will drive adoption activity in the rest of the clinician market.
- Supported by clinical validation publication in *Frontiers in Cellular & Infection Microbiology*, reporting >99% median specificity and 91% median sensitivity across 176 clinically relevant targets

Sub-Section 2.3

Supplement Results

Supplement growth focused on Invivo branded products



- Invivo branded and owned supplements delivered \$0.68m, up 7% vs PCP.
- Leading PHGG prebiotic supplement volumes delivered 12,063 units in Q3, up 161% vs PCP
- A subscription offering was launched in October, and it has already grown to over 800 subscribers.
- The supplement business continues to accelerate its transition to high margin own label Invivo products (from distributed products).

Sub-Section 2.4

Therapeutic Partnering

Pipeline of assets backed by big-data, preclinical and clinical validation, targeting deals

- 5+ years of investment to develop a rich pipeline of live biotherapeutic assets and data, leveraging Microba's world leading databank generated from it's testing business
- Multiple microbiome therapeutics sector read outs delivered between Nov-25 and Feb-26 validating the modality for pharma partners
- The team are active in partnering, and have intensified its partnering activities for its field leading assets
- Recent deal precedents ranging between \$1.5 – \$11B

LBP = Live Biotherapeutic Product

Therapeutic Assets

Core Program		Discovery R&D	Preclinical	Phase 1	Phase 2	Development Partners
IBD (Ulcerative colitis)	MAP 315 (LBP)				Phase 2 IND submission currently being compiled	  
	Undisclosed (LBP)					
Immuno-oncology	Undisclosed (LBP)			Pre-clinical biology supporting lead candidate selection		 
Autoimmune	Undisclosed (LBP)			Laboratory & animal model experiments confirming activity		

Deal Catalysts

The results from these trials if positive, validate this new live-biotherapeutic modality, and create a deal environment for Microba's best in class assets.



Vedanta – Global, randomized, double-blind, placebo-controlled Phase 2 study COLLECTiVE202, for VE202 in patients with mild-to-moderate UC. **13 Aug 2025 - did not meet their end points.**



Siolta - Phase 1b/2, randomized, double-blind, multi-center study to evaluate the preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease. **17 Nov 2025 - met their end points.**



Maat Pharma - Phase 3 ARES trial, evaluating Xervyteg® (MaaT013) in gastrointestinal acute Graft-versus-Host Disease patients. – **8 Dec 2025 – positive final pivotal results. Under regulatory review by the European Medicines Agency for Market Approval – decision expected mid-2026.**



EnteroBiotix - Phase 2a TrLuMPH trial, for EBX-102-02 in irritable bowel syndrome (IBS) patients. **8 Jan 2026 - met their end points.**



Microbiotica - Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis (UC) patients. **11 Feb 2026 - met their end points.**

Sub-Section 2.5

Focus & Catalysts

Key areas of focus & catalysts

Diagnostics

- Australia - continued growth in test sales and clinical adoption
- United Kingdom - continued growth in test sales and clinical adoption
- New test release
- Clinical integration platform release

Therapeutics

- Active in partnering off the back of recent positive sector trial readouts
- Additional sector catalysts, expected in early CY2026.

FY26 Guidance

- Regional Break-even in Australia & United Kingdom
- >24,000 Core test volume (Q3 annualised run rate of 23,000+)

Corporate Snapshot

ASX Code	MAP
Market capitalisation ¹	\$42.62m
Shares on issue	608.96m
52-week low / high ¹	\$0.067 / \$0.23
Cash Balance (31 Mar 2026)	\$7.28m

Major Shareholders

Shareholder	Ownership % ²
Sonic Healthcare	21.68%
Perennial	12.02%
Thorney Investment Group	5.88%
Mercer Investments (Australia)	6.37%
SA Microba Holdings	5.50%

¹ At 29 April 2026 | ² As per latest substantial shareholder notice lodged to the ASX



Dr Luke Reid

Chief Executive Officer

luke.reid@microba.com



Pasquale Rombola

Chair

pasquale.rombola@microba.com

Contact

Head Office

Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory

Princess Alexandra Hospital
Woolloongabba QLD Australia